Renin–angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis

AN Koshy; AC Murphy; O Farouque; J Ramchand; LM Burrell; MB Yudi

Journal article

Renin–angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis

AN Koshy, AC Murphy, O Farouque, J Ramchand, LM Burrell, MB Yudi

Internal Medicine Journal | WILEY | Published : 2020

DOI: 10.1111/imj.15002

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, enters human cells by binding of its viral protein to the aminopeptidase angiotensin-converting enzyme 2 (ACE2). This has led to speculation whether treatment with renin–angiotensin system (RAS) inhibitors was associated with an increased likelihood of a positive test for COVID-19 and risk of mortality. Aims: We performed a systematic review and meta-analysis to investigate whether RAS inhibitors increased the likelihood of a positive test or death/severe illness in patients with COVID-19. Methods: A systematic search of MEDLINE, PubMed and EMBASE was conducted for studies stratified by..

View full abstract

University of Melbourne Researchers

Omar Farouque Author

Louise Burrell Author

Anoop Koshy Author

Related Projects (1)

CARDIAC DYSFUNCTION IN ADVANCED LIVER DISEASE AND AFTER LIVER TRANSPLANTATION

Heart disease is the leading cause of early death after liver transplantation (LT). The scarcity of donor organs means that LT is a limited ..

Grants

Awarded by Cardiac Society of Australia and New Zealand

Funding Acknowledgements

A. N. Koshy is a recipient of the National Health and Medical Research Council of Australia/National Heart Foundation Post-Graduate Scholarship and Royal Australasian College of Physicians Blackburn Scholarship (1150874). A. C. Murphy is supported by the Cardiac Society of Australia and New Zealand PhD Scholarship.